Access to essential medicines for children with cancer: a joint SIOP-CCI position statement

Elsevier, The Lancet Oncology, January, 2017
Authors: 
Denburg A, Arora B, Arora RS, Auste C, Bagai P, Barr, Challinor J, Eden T, Grynzspancholc, Hoffman R, Link M

Abstract

Treatment of cancer in childhood is both a major success of modern medicine and a stark reminder of its limits. In high-income countries, multimodality therapy cures more than 80% of children.1 In low-income and middle-income countries (LMICs), where most children with cancer live, far fewer children are cured than in high-income countries. Access to essential medicines is one of the key determinants of cancer survival globally. WHO's Essential Medicines List (EML) sets the basic bar that all national governments should meet in provision of medicines.